Public Law Challenges to the Regulation of Pharmaceutical Patents in the US Bilateral Free Trade Agreement
Public Law Challenges to the Regulation of Pharmaceutical Patents in the US Bilateral Free Trade Agreement
复制标题
美国双边自由贸易协定中药品专利监管的公法挑战
DOI：
10.1017/cbo9780511750786.006
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Hitoshi Nasu
中科院分区：
文献类型：
--
作者：
Hitoshi Nasu
随着世界贸易组织（“WTO”）的制度化和司法化，国际贸易法体系不断蓬勃发展。虽然有些人对宪政化的发展表示欢迎，但法律制度的政府间性质，特别是在立法阶段，仍然处于半暗状态。世贸组织制度下的药品专利保护对基本药物的获取造成的障碍就是一个例证。跨国论坛上缓解这一问题的压力越来越大，但美国通过双边贸易协定对医药产品制定更高水平知识产权保护的倡议却阻碍了变革。
The international trade law regime has been flourishing with the institutionalisation and judicialisation under the auspices of the World Trade Organization (‘WTO’). While some people applaud the development towards constitutionalisation, the inter-governmental nature of the legal regime, especially at the law making phase, has remained at the penumbra. Illustrative is the barrier against access to essential medicines caused by pharmaceutical patent protection under the WTO regime. Pressures have been mounting to alleviate the problem in multinational forums, and yet the initiative by the United States to set a higher level of intellectual property protection over pharmaceutical products through bilateral trade agreements has impeded change.